168 related articles for article (PubMed ID: 23860238)
1. Differential diagnosis of reactive mesothelial cells and malignant mesothelioma cells using the cell proliferation markers minichromosome maintenance protein 7, geminin, topoisomerase II alpha and Ki-67.
Kimura F; Okayasu I; Kakinuma H; Satoh Y; Kuwao S; Saegusa M; Watanabe J
Acta Cytol; 2013; 57(4):384-90. PubMed ID: 23860238
[TBL] [Abstract][Full Text] [Related]
2. Significance of cell proliferation markers (Minichromosome maintenance protein 7, topoisomerase IIalpha and Ki-67) in cavital fluid cytology: can we differentiate reactive mesothelial cells from malignant cells?
Kimura F; Kawamura J; Watanabe J; Kamoshida S; Kawai K; Okayasu I; Kuwao S
Diagn Cytopathol; 2010 Mar; 38(3):161-7. PubMed ID: 19821496
[TBL] [Abstract][Full Text] [Related]
3. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
4. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
5. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
6. Minichromosome maintenance-7 and geminin are reliable prognostic markers in patients with oral squamous cell carcinoma: immunohistochemical study.
Tamura T; Shomori K; Haruki T; Nosaka K; Hamamoto Y; Shiomi T; Ryoke K; Ito H
J Oral Pathol Med; 2010 Apr; 39(4):328-34. PubMed ID: 20136698
[TBL] [Abstract][Full Text] [Related]
7. Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours.
Vargas PA; Cheng Y; Barrett AW; Craig GT; Speight PM
J Oral Pathol Med; 2008 May; 37(5):309-18. PubMed ID: 18248354
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of topoisomerase II alpha and evaluation of its effects on cell proliferation and apoptosis in glioblastoma cancer stem cells.
Hong Y; Sang M; Shang C; Xue YX; Liu YH
Neurosci Lett; 2012 Jun; 518(2):138-43. PubMed ID: 22569122
[TBL] [Abstract][Full Text] [Related]
9. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
Hasteh F; Lin GY; Weidner N; Michael CW
Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
[TBL] [Abstract][Full Text] [Related]
10. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
Afify AM; Stern R; Michael CW
Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
[TBL] [Abstract][Full Text] [Related]
12. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
Shield PW; Koivurinne K
Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
[TBL] [Abstract][Full Text] [Related]
13. [Mesothelial cell. Cytology. Cytochemistry. Immunocytochemistry. Contribution of immunolabelling to the cytodiagnosis of serous effusions with cells of mesothelial aspect].
Marsan C; Gaulier A; Sabatier P; Garcia R
Arch Anat Cytol Pathol; 1993; 41(5-6):223-8. PubMed ID: 8135583
[TBL] [Abstract][Full Text] [Related]
14. Expression of minichromosome maintenance 7 (MCM7) in small lung adenocarcinomas (pT1): Prognostic implication.
Fujioka S; Shomori K; Nishihara K; Yamaga K; Nosaka K; Araki K; Haruki T; Taniguchi Y; Nakamura H; Ito H
Lung Cancer; 2009 Aug; 65(2):223-9. PubMed ID: 19144445
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical study on topoisomerase IIalpha, Ki-67 and cytokeratin-19 in oral lichen planus lesions.
Mattila R; Alanen K; Syrjänen S
Arch Dermatol Res; 2007 Jan; 298(8):381-8. PubMed ID: 17072627
[TBL] [Abstract][Full Text] [Related]
16. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
[TBL] [Abstract][Full Text] [Related]
17. ProEx C as an adjunct marker to improve cytological detection of urothelial carcinoma in urinary specimens.
Moatamed NA; Rao JY; Alexanian S; Cobarrubias M; Levin M; Lu D; Apple SK
Cancer Cytopathol; 2013 Jun; 121(6):320-8. PubMed ID: 23364848
[TBL] [Abstract][Full Text] [Related]
18. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic usefulness of MUC1 and MUC4 for distinguishing between metastatic adenocarcinoma cells and reactive mesothelial cells in effusion cell blocks.
Cho JS; Kim GE; Lee JS; Lee JH; Nam JH; Choi C
Acta Cytol; 2013; 57(4):377-83. PubMed ID: 23860190
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of osteopontin in epithelioid mesotheliomas and reactive mesothelial proliferations.
Tigrani DY; Weydert JA
Am J Clin Pathol; 2007 Apr; 127(4):580-4. PubMed ID: 17369133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]